Safety of HRX215 in Patients After Minor and Major Liver Resection

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 6, 2025

Primary Completion Date

December 1, 2025

Study Completion Date

July 1, 2026

Conditions

Colorectal Liver MetastasesLiver Resection

Interventions

DRUG

HRX215 capsules

HRX215 capsules 250 mg orally twice daily

DRUG

Placebo capsules

placebo capsules matching appearance of HRX215

Trial Locations (1)

RECRUITING

Mayo Clinic, Rochester